New perspectives in glioma immunotherapy

Gene carriers and transfection systems used in the recombination of dendritic cells for effective cancer immunotherapy

Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma

Guiding the „misguided“ – functional conditioning of dendritic cells for the DC-based immunotherapy against tumours

Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy

Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients

New approaches to the development of adenoviral dendritic cell vaccines in melanoma

Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used

An autologous dendritic cell canine mammary tumor hybrid-cell fusion vaccine

Dendritic cell-based immunotherapy for prostate cancer